Targeted therapy for T-cell lymphoma that didn't respond to first treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of targeted drugs (including an EZH2 inhibitor) for people with peripheral T-cell lymphoma (PTCL) that didn't respond to their first treatment. The drugs are chosen based on the genetic mutations in your tumor, aiming to attack the cancer more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have peripheral T-cell lymphoma (PTCL), a rare type of blood cancer
- Your lymphoma did not go away after your first chemotherapy treatment (like CHOP)
- You have had a genetic test (genotyping) done on your tumor
- You are generally able to care for yourself (ECOG score 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an oral drug (azacytidine) plus romidepsin works better than a standard “doctor’s choice” treatment for people with relapsed or refractory peripheral T-cell lymphoma. It’s for adults whose disease has come back or did not respond after prior treatment.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
This trial tests a new drug called zeprumetostat (an EZH2 inhibitor) combined with other treatments for people with mature T-cell or NK-cell lymphoma that has come back or not responded to standard therapy. The goal is to see if the combination can help control the lymphoma.
This study tests a new drug, zeprumetostat, combined with other treatments for people with a type of lymphoma that has come back or not responded to previous therapy. The goal is to see if these combinations can help control the cancer.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.